SWISS ~ BRIDGE

INVEST IN CANCER RESEARCH WORLDWIDE

SWISS BRIDGE AWARD 2024



AWARD 2024

Early Phase Clinical Trials

Since 2000, the SWISS BRIDGE AWARD has been granted to support high-quality cancer research projects in Europe. This year, young investigators (under the age of 45 holding a PhD or MD) with projects focusing on Early Phase Clinical Trials are eligible for application.

Early Phase Clinical Trials Topic: CHF 500'000 Prize money:

The award ceremony for this year's winners of the SWISS BRIDGE AWARD 2024 will take place on October 22, 2024 at noon at the magnificently situated Restaurant Heugümper in Zurich. If you would like to be present at the ceremony, please use the attached form or send us an email: info@swissbridge.ch

SAVE THE DATE!

Golf-Event Golf Club Lenzerheide Tuesday, August 27, 2024











SWISS ~ BRIDGE

INVEST IN CANCER RESEARCH WORLDWIDE

WHY SWISS BRIDGE

What sets us apart from the rest in the field of cancer research? It is the extremely positive feedback we continousely receive from all our partners:



Distinguished reputation of the SWISS BRIDGE Award



Identification of specific projects in Switzerland and in other countries



Professional scientific jury



Designated donations are made available in full to screened and selected cancer researches & projects



Low cost for advertising, PR, IT and fees, covered by supporters & friends of the foundation

This unique concept enables us to look to the future with optimism and take another important step in the fight against cancer!

In 2024, we will again support numerous research projects, some of which we have listed in this newsletter. The SWISS BRIDGE AWARD is also currently in its critical phase, and we look forward to seeing which scientists the SWISS BRIDGE Scientific Jury will select as winners.

Donations: Credit Suisse · 8070 Zurich · IBAN: CH52 0483 5095 7385 1100 0

ORGANIZATION

Board of Foundation

Prof. Dr. Jakob Passweg (Chairman) Eleonore E. Droux, Herrliberg Dr. Thomas Peter, Küsnacht Yves Monnard, St. Gallen Liv Bahner, Zurich

Scientific Jury

Prof. Dr. Adrian Ochsenbein (Chairman)

Honory Chairman Prof. Dr. Giorgio Noseda

Management Philipp Lücke (CEO)

Board of Patrons

Dr. med. Jaques Bernier, Geneva Prof. Dr. med. Dr. h.c. Urs Metzger, Zurich Sir Paul Nurse, London Heinz Roth, Uitikon/ Waldegg Prof. Dr. med. Thomas Szucs, Zollikon

Administration

SWISS BRIDGE Foundation P.O. Box 1556, 8027 Zurich Phone + 41 (0) 43 31 71 360 info@swissbridge.ch



INVEST IN CANCER RESEARCH WORLDWIDE

- PREFACE
- SWISS BRIDGE AWARD 2023
- WHY SWISS BRIDGE
- **SUMMARY OF CURRENT PROJECTS 2024**
- SWISS BRIDGE AWARD 2024
- SWISS BRIDGE GOLF EVENT 2024
- ORGANIZATION





April 2024





www.swissbridge.ch

SWISS ~ BRIDGE

INVEST IN CANCER RESEARCH WORLDWIDE

Dear friends of the SWISS BRIDGE Foundation

With the help of your support, we have been able to achieve so much over the past 27 years. The days when a cancer diagnosis was a death sentence are long gone, and cancer patients are receiving better and better care.

Nevertheless, there is still much to do! Not only is it essential to further improve the chances of recovery for those affected, but cancer must also be prevented from developing in the first place. This newsletter highlights the activities we have promoted over the past year, so that we can duly acknowledge the projects you support and we assist. Please see the attached overview for insights into our currently funded research projects.

The SWISS BRIDGE AWARD, one of the most highly endowed cancer prizes in Europe, was once again an amazing success in 2023, and in 2024, it will be conferred for the 25th time. Your support has made funding high-level cancer research projects possible, both in Switzerland and abroad. SWISS BRIDGE would be delighted to see your continued involvement. Please challenge us!

Thank you, dear reader, for your interest, your support, your commitment, your involvement and especially for your trust.

We hope you enjoy reading this issue and look forward to continuing our successful collaboration.

With kind regards,



Prof. Dr. Jakob Passweg President

Jahr Panwey



Philipp Lücke CEO

Ple. Cincke

S W I S S B R I D G E

INVEST IN CANCER RESEARCH WORLDWIDE


SWISS BRIDGE AWARD 24. October 2023



This year's award ceremony took place at the traditional Restaurant Heugümper in Zurich. After the keynote speech by the President of SWISS BRIDGE Prof. Dr. Jakob Passweg, the two winners for 2023 were duly honored by the Chairman of the Scientific Jury Prof. Dr. Adrian Ochsenbein.

Resistance to cancer therapies: Half a million Swiss francs for two research projects

Two researchers from Austria and Switzerland receive the **SWISS BRIDGE Award 2023** for their promising research projects. The prize money of 250'000 francs each will contribute to a better understanding of the development of therapy resistance in cancers and to finding new treatment options.



Lukas Flatz

(MD)

Institute of Immunobiology Kantonsspital St. Gallen Rorschacherstrasse 95 9007 St. Gallen Switzerland

We are planning a visit to Prof. Flatz's laboratory soon, where you can have him and his team explain their research activities to you. If you would like to attend in person, please let us know by returning the enclosed reply form.



Anna Christina Obenauf

(PhD)

Research Institute of Molecular Pathology (IMP) Campus-Vienna-Biocenter 1 1030 Vienna Austria

At the luncheon afterwards, all guests had the opportunity to discuss the latest developments in cancer research with current and former prizewinners.

Would you like to see the detailed project descriptions? Simply tick the box on the reply form.

SWISS ~ BRIDGE

INVEST IN CANCER RESEARCH WORLDWIDE

SUMMARY OF CURRENT PROJECTS 2024

Title: Childhood Cancer, Targeting the kinome in oncofusion-driven pediatric gliomas

Research lead: Dr. MD PhD Ana S. Stücklein, Department of Oncology and Children's Research Center, University Children's Hospital Zurich

Budget: CHF 125'000 p.a.

Title: Development of a new surgical technique to de-escalate axillary surgery for breast cancer

Research lead: Prof. Dr. Walter P. Weber, Head of Division Breast Surgery, University Hospital Basel Budget: CHF 284'000

Title: Autophagy: a potential new approach to the treatment of lymphoma

Research lead: Prof. Dr. med. Urban Novak, Deputy Chief Physician, University Clinic for Medical Oncology Bern

Budget: CHF 226'600 p.a.

Title: Development of new therapies for men with metastatic prostate cancer

Research lead: Prof. Dr. med. Mark A. Rubin, Department for Biomedical Research (DBMR), Universität Bern; Prof. Nicola Aceto, Department of Biology, ETH Zürich; Dr. med. Dilara Akhoundova Sanoyan, Medizinische Onkologie, Inselspital, Bern

Budget: CHF 343'650

Title: Development of novel therapies for cervical cancer

Research lead: Prof. Dr. Douglas Hanahan, Swiss Institute for Experimental Cancer Research (ISREC), Swiss Federal Institute of Technology Lausanne

Budget: CHF 150'000 p.a.

Title: Childhood Cancer: Identifying novel therapeutic targets for childhood brain tumors using CRISPR in vivo screens in orthotropic mouse models

Research lead: Dr. PhD David T.W. Jones, Hopp Children's Cancer Center Heidelberg Budget: EUR 125'000 p.a.

Title: Natural killer cells as immunotherapy in patients with leukemia

Research lead: Dr. med. Laurent Schmied, Clinic for Hematology, University Hospital Basel Budget: CHF 165'000 p.a.

Curious about how to support a project?

With the help of our scientific jury, we would be pleased to find individual cancer research projects for you in Switzerland or abroad. Please get in touch!



